Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    1383436 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Drug: Bevacizumab;   Drug: Lenalidomide;   Drug: Docetaxel;   Drug: Prednisone

Indicates status has not been verified in more than two years